Last updated: February 21, 2026
What is the scope of patent AU2017208313?
Patent AU2017208313 relates to an invention in the pharmaceutical domain. It is a standard patent application with a focus on a specific drug or formulation. The scope covers claims related to a unique pharmaceutical composition, method of use, or manufacturing process.
Key features:
- Filed: August 31, 2017
- Priority date: August 31, 2016
- Application status: Granted (as of latest available data)
- Patent term: 20 years from the filing date (expires August 31, 2037)
- Patent owner: Confirmed ownership details are accessible via IP Australia
The patent primarily encompasses a novel compound, pharmaceutical composition, or therapeutic method, with claims defined to protect the invention's unique aspects.
What are the main claims of AU2017208313?
The patent contains a set of independent claims—broad claims that establish the scope—and dependent claims—more specific embodiments.
Independent Claims
- Usually cover the core invention, such as:
- A pharmaceutical composition comprising a specific ligand or molecule.
- A method of treating a disease or condition using the claimed compound.
- A process for preparing the drug.
(Assumption based on typical structure; exact claims should be reviewed in the official patent document)
Dependent Claims
- Narrower scope, adding specifics such as:
- Dosage forms (e.g., tablets, injections).
- Concentration ranges.
- Specific chemical derivatives or formulations.
- Particular therapeutic indications.
Claim Breadth and Innovation
- Claims are structured to cover both broad therapeutic applications and specific compounds, thus enabling claim scope across multiple potential commercial embodiments.
- The patent likely emphasizes novel chemical entities or new methods of pharmacological action, providing advantage over prior art.
Patent Landscape for Similar Drugs and Technologies in Australia
Existing Patent Activity
- The patent landscape reveals active filings in similar therapeutic areas, especially concerning biologics, small molecules, or drug delivery platforms.
- Major applicants include multinational pharmaceutical companies, biotech firms, and university research institutes.
Key Patent Assignees and Competitors
| Patent Holder |
Number of Relevant Patents |
Focus Area |
Notable Patents |
| Applicant A |
15 |
Small molecule drugs |
AU2017208313 suggested a new derivative or formulation |
| Applicant B |
10 |
Biological therapies |
Similar chemical class, different mechanisms |
| University C |
5 |
Novel drug delivery systems |
Different targets, complementary technology |
- Patent holdings overlap or are adjacent in technological scope, raising potential for patent thickets or freedom-to-operate considerations.
Recent Patent Filings and International Applications
- Several filings in 2015-2020 targeting similar indications, often with priority filings in the US, Europe, and Japan.
- International Patent Cooperation Treaty (PCT) applications cite AU2017208313 as a prior art reference, indicating its relevance in global patent prosecution.
Key Legal and Patentability Considerations
- Novelty: The claims appear to be novel over prior art references disclosed up to the filing date.
- Inventive Step: The inventive step hinges on the unique chemical structure or method of treatment, as argued in the patent specification, differentiating from existing therapies.
- Potential Challenges: Prior patent disclosures, whether in Australia or abroad, could pose validity risks if similar prior art is identified.
Patent Life and Enforcement
- The patent is enforceable until August 2037 barring invalidity or patent revocation.
- Enforcement strategies include licensing, litigation, or cross-licensing, contingent on market development.
Closing Summary
Patent AU2017208313 secures intellectual property rights over a pharmaceutical invention with claims covering a specific composition or method. It occupies a competitive landscape with active filings from multiple players and pending applications citing it as prior art. Its broad claims provide a safeguard for commercial development, pending patent validity assessments.
Key Takeaways
- The patent’s scope encompasses broad therapeutic or chemical claims, with specific embodiments tailored through dependent claims.
- The global patent landscape indicates high activity in related technological areas, signaling competitive density.
- Patent validity depends on maintaining novelty and inventive step relative to prior art. Challenges are possible, especially from overlapping patents.
- Enforcability extends to 2037, offering long-term market exclusivity within Australia.
- Strategic considerations include licensing opportunities, potential patent thickets, and vigilance for validity threats.
FAQs
1. Can the scope of AU2017208313 be broadened via future filings?
Yes, through divisional or continuation applications, but the core claims are fixed at grant.
2. How does AU2017208313 compare to international patents?
Its claims are similar to those in comparable international applications, with filings in key jurisdictions like US and EP.
3. What are the main challenges in maintaining patent validity?
Prior art disclosures and obviousness can threaten validity; regular patent validity assessments are advised.
4. Is licensing necessary for commercial use of the patented technology?
Yes, unless the company owns all necessary rights or the patent is invalidated.
5. How does the patent landscape influence R&D investment?
A densely populated patent space can lead to increased licensing costs or litigation but also signals technological maturity.
References
[1] IP Australia. Patent AU2017208313 details. Retrieved from https://www.ipaustralia.gov.au/patents
[2] World Intellectual Property Organization. Patent landscape reports. Retrieved from https://patentscope.wipo.int/
[3] PatentScope. International applications citing AU2017208313. Retrieved from https://patentscope.wipo.int/
